Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance study of amiselimod in healthy men
NCT02293967Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Sep 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of amiselimod in relapsing-remitting multiple sclerosis (RRMS), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Total radioactivity in urine and faeces up to 10 weeks. Started Sep 2014; status: completed.
02
Drugs
amiselimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02293967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02293967.